Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-502 Topical Solution in Alopecia Areata
NCT03759340Phase 2
Key facts
- Status
- Terminated
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Countries
- 1
- Sponsor
- Aclaris Therapeutics, Inc.
- Modality
- Small Molecules
- Drugs
- ifidancitinib
- Conditions
- alopecia areataalopecia universalis (AU)alopecia totalis (AT)
01
Overview
Phase 2, open-label, single-arm trial of ifidancitinib in alopecia areata, alopecia universalis (AU) and alopecia totalis (AT), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Change in Severity of Alopecia Tool Score at 24 weeks. Started Jan 2019; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
ATI 502 0.46% Topical Solution
Subjects apply ATI-502 Topical Solution, 0.46% twice-daily.
03
Endpoints
Primary
Change in Severity of Alopecia Tool Score
Secondary
Mean Relative Percent Change From Baseline SALT Score
Proportion of Subjects Achieving a SALT50
Proportion of Subjects Achieving a SALT75
Durability of Response
Change From Baseline in the Physician Global Impression of Severity
Beyond the preview
Go deeper on NCT03759340.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759340.